Nigel Crockett
Corporate Officer/Principal at BICYCLE THERAPEUTICS PLC
Net worth: 1 M $ as of 2024-03-30
Nigel Crockett active positions
Companies | Position | Start | End |
---|---|---|---|
BICYCLE THERAPEUTICS PLC | Corporate Officer/Principal | 2019-10-28 | - |
Career history of Nigel Crockett
Former positions of Nigel Crockett
Companies | Position | Start | End |
---|---|---|---|
The Bioindustry Association
The Bioindustry Association Miscellaneous Commercial ServicesCommercial Services The BioIndustry Association is a UK-based organization that represents the life sciences and biotech industry. The British company's mission is to facilitate and connect the ecosystem to help businesses start, grow, and deliver world-changing innovation. The non-profit company was founded by Cormac G. Kilty and Simon Geoffrey Best, and Steve Bates has been the CEO of the company since 2012. | Corporate Officer/Principal | - | - |
Tukan Partners Ltd. | Founder | 2004-12-31 | - |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | Corporate Officer/Principal | - | - |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | Director/Board Member | 2009-11-01 | - |
Astex Therapeutics Ltd.
Astex Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Astex Therapeutics Ltd. engages in the provision of drug discovery and development activities. Its proprietary fragment-based drug discovery platform, Pyramid, delivers drug leads on therapeutic targets and disease areas.The company was founded by Harren Jhotin, Roberto Solari, Stephen W. Bunting, Christopher Abell, and Thomas L. Blundell in 1999 and is headquartered in Cambridge, the United Kingdom. | Corporate Officer/Principal | - | - |
Procarta Biosystems Ltd.
Procarta Biosystems Ltd. Pharmaceuticals: MajorHealth Technology Procarta Biosystems Ltd. develops deoxyribonucleic acid based therapeutics and antibacterials. The company was founded by Michael McArthur and Mervyn Bibb on March 1, 2007 and is headquartered in Norwich, the United Kingdom. | Director/Board Member | 2010-01-06 | - |
Corporate Officer/Principal | - | - |
Training of Nigel Crockett
The University of Manchester | Undergraduate Degree |
University of Cambridge | Doctorate Degree |
Statistics
International
United Kingdom | 10 |
Operational
Corporate Officer/Principal | 5 |
Director/Board Member | 2 |
Doctorate Degree | 1 |
Sectoral
Health Technology | 5 |
Consumer Services | 3 |
Commercial Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
BICYCLE THERAPEUTICS PLC | Health Technology |
Private companies | 6 |
---|---|
Astex Therapeutics Ltd.
Astex Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Astex Therapeutics Ltd. engages in the provision of drug discovery and development activities. Its proprietary fragment-based drug discovery platform, Pyramid, delivers drug leads on therapeutic targets and disease areas.The company was founded by Harren Jhotin, Roberto Solari, Stephen W. Bunting, Christopher Abell, and Thomas L. Blundell in 1999 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | Health Technology |
The Bioindustry Association
The Bioindustry Association Miscellaneous Commercial ServicesCommercial Services The BioIndustry Association is a UK-based organization that represents the life sciences and biotech industry. The British company's mission is to facilitate and connect the ecosystem to help businesses start, grow, and deliver world-changing innovation. The non-profit company was founded by Cormac G. Kilty and Simon Geoffrey Best, and Steve Bates has been the CEO of the company since 2012. | Commercial Services |
Procarta Biosystems Ltd.
Procarta Biosystems Ltd. Pharmaceuticals: MajorHealth Technology Procarta Biosystems Ltd. develops deoxyribonucleic acid based therapeutics and antibacterials. The company was founded by Michael McArthur and Mervyn Bibb on March 1, 2007 and is headquartered in Norwich, the United Kingdom. | Health Technology |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | Commercial Services |
Tukan Partners Ltd. |
- Stock Market
- Insiders
- Nigel Crockett
- Experience